Drug Profile
Nelonemdaz - GNT Pharma
Alternative Names: NEU-2000; Neu2000; Neu2000KL; SalfaprodilLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Amkor Pharma
- Developer AmKor Pharma; GNT Pharma
- Class Amines; Anti-ischaemics; Benzoic acids; Cardiovascular therapies; Fluorobenzenes; Neuroprotectants; Small molecules; Vascular disorder therapies
- Mechanism of Action Antioxidants; NMDA receptor antagonists; NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Stroke
- Phase II Heart arrest
- No development reported Brain injuries; Burns; Myocardial infarction; Spinal cord injuries
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Brain injuries in South Korea (IV, Infusion)
- 28 May 2023 No recent reports of development identified for phase-I development in Burns in South Korea (IV, Infusion)
- 28 May 2023 No recent reports of development identified for phase-I development in Spinal-cord-injuries in South Korea (IV, Infusion)